Novel prospective umbrella ‐type lung cancer registry study for clarifying clinical practice patterns: CS‐Lung‐003 study protocol
DiscussionWe successfully launched the umbrella ‐type CS‐Lung‐003 registry. Under this single registry, researchers collaborate on patient registration and data provision for their own and other studies. Thus, the registry will produce results for multiple domains of study, providing answers to questions about lung cancer treatment raised b y other researchers. Through such analysis of each linked study, this registry will contribute to the comprehensive elucidation of actual daily practice patterns in lung cancer treatment.Key points CS ‐Lung‐003 registry directly integrates multiple linked studies created under...
Source: Thoracic Cancer - January 12, 2021 Category: Cancer & Oncology Authors: Kazuya Nishii, Masaaki Inoue, Hideto Obata, Yutaka Ueda, Toshiyuki Kozuki, Masahiro Yamasaki, Tomonori Moritaka, Yoshikazu Awaya, Keisuke Sugimoto, Kenichi Gemba, Shoichi Kuyama, Hirohisa Ichikawa, Takuo Shibayama, Tetsuya Kubota, Masahiro K Tags: STUDY PROTOCOL Source Type: research

Clinical utility of the C ‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab
ConclusionsFor second ‐line nivolumab therapy, evaluation of baseline CAR and subsequent changes in CAR may be predictive of therapeutic response to nivolumab and long‐term survival in NSCLC patients.Key pointsSignificant findings of the studyThe baseline value of C ‐reactive protein:albumin ratio was significantly associated with one‐year mortality and overall survival in non‐small cell lung cancer patients treated with nivolumab.What this study addsTime ‐series change of C‐reactive protein:albumin ratio may be useful for predicting the treatment efficacy in patients treated with nivolumab. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 12, 2021 Category: Cancer & Oncology Authors: Taisuke Araki, Kazunari Tateishi, Kei Sonehara, Shuko Hirota, Masamichi Komatsu, Manabu Yamamoto, Shintaro Kanda, Hiroshi Kuraishi, Masayuki Hanaoka, Tomonobu Koizumi Tags: ORIGINAL ARTICLE Source Type: research

Early ‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non ‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertinib due to elevated mesenchymal epithelial transition (MET) copy number amplification. However, early‐ onset interstitial pneumonitis occurred within two days. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 12, 2021 Category: Cancer & Oncology Authors: Yuan Cheng, Qing Yu, Yan Xiong, Cuiyan Guo, Ligong Nie Tags: CASE REPORT Source Type: research

Ruptured pseudoaneurysm of the thoracic aorta mimicking lung cancer: A case report
PTA shows stable hemodynamics, but the risk of rupture is extremely high and frequently fatal. To assist in the differential diagnoses, clinicians need to be familiar with imaging findings of PTA. AbstractA 70 ‐year‐old woman was admitted to a local hospital with a five‐day history of back pain. She had been referred to our hospital after an abnormal chest shadow was identified on chest X‐ray. Chest computed tomography (CT) revealed an anterior mediastinal mass in the upper lobe of the left lung. Her general condition was good. She was diagnosed with lung cancer, and examination was planned. However, respiratory fa...
Source: Thoracic Cancer - January 9, 2021 Category: Cancer & Oncology Authors: Yutaka Takahara, Kazuaki Nishiki, Keisuke Nakase, Shiro Mizuno Tags: CASE REPORT Source Type: research

Uniportal video ‐assisted thoracoscopic left pneumonectomy: Retrospective analysis of eighteen consecutive patients from a single center
ConclusionsUniportal video ‐assisted thoracoscopic left pneumonectomy is a safe and feasible procedure for selected lung cancer patients. The use of uniportal VATS in right pneumonectomies and the effect of uniportal video‐assisted thoracoscopic pneumonectomy on the survival of patients merits further study.Patients receiving uniportal VATS pneumonectomies had standard surgical results and recovery. Uniportal VATS pneumonectomy is safe for properly selected lung cancer patients.Key pointsSignificant findings of the study: • Patients receiving uniportal VATS left pneumonectomies had standard surgical results and re...
Source: Thoracic Cancer - January 6, 2021 Category: Cancer & Oncology Authors: Jiagen Li, Qi Xue, Yushun Gao, Yousheng Mao, Jun Zhao, Shugeng Gao Tags: ORIGINAL ARTICLE Source Type: research

Response to: Estimated direct costs of non ‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model
Thoracic Cancer, EarlyView. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 6, 2021 Category: Cancer & Oncology Authors: Lisha Jiang, Kun Zhou, Guowei Che, Hongsheng Ma Tags: Letter to the Editor Source Type: research

Non ‐small cell lung cancer with gastric metastasis and repeated gastrointestinal bleeding: A rare case report and literature review
Non ‐small cell lung cancer (NSCLC) with gastric metastasis is rarely reported. Recurrent gastrointestinal bleeding prevents treatment. Palliative total gastrectomy is feasible in these patients. AbstractThe occurrence of gastrointestinal metastasis from lung carcinoma is rare. Compared with non ‐small cell lung cancer (NSCLC), small cell lung cancer more commonly results in this sort of metastasis. Here, we report an unusual case of NSCLC initially without evidence of distant metastasis that developed into gastric metastasis five months after the initial diagnosis, despite the primary lu ng cancer having a partial res...
Source: Thoracic Cancer - January 5, 2021 Category: Cancer & Oncology Authors: Chang Shih ‐Chun, Huang Shih‐Chiang, Tsai Chun‐Yi, Wang Shan‐Yu, Liu Keng‐Hao, Hsu Jun‐Te, Yeh Ta‐Sen, Yeh Chun‐Nan Tags: CASE REPORT Source Type: research

Electromagnetic navigation bronchoscopic localization versus percutaneous CT ‐guided localization for thoracoscopic resection of small pulmonary nodules
ConclusionsElectromagnetic navigation bronchoscopic injection techniques using indocyanine green fluorescence plus iopamidol are safe and effective, and comparable with CT ‐guided localization. Furthermore, a bronchoscopic approach enables marking of multiple lesion areas without increasing patient risk, especially for puncture‐related pneumothorax.Key pointsSignificant findings of the study Either computed tomography (CT) ‐guided percutaneous or electromagnetic navigation bronchoscopic injection techniques can be used for preoperative marking of pulmonary nodules with indocyanine green (ICG) fluorescence.What this s...
Source: Thoracic Cancer - January 4, 2021 Category: Cancer & Oncology Authors: Yan ‐Long Yang, Zi‐Zhe Li, Wei‐Chao Huang, Jia Zhuang, Dai‐Ying Lin, Wen‐Zhao Zhong, Bin Lan Tags: ORIGINAL ARTICLE Source Type: research

Corrigendum
Thoracic Cancer, Volume 12, Issue 1, Page 142-142, January 2021. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 3, 2021 Category: Cancer & Oncology Tags: CORRIGENDUM Source Type: research

Issue Information
Thoracic Cancer, Volume 12, Issue 1, Page 1-2, January 2021. (Source: Thoracic Cancer)
Source: Thoracic Cancer - January 3, 2021 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

Thymic epithelial tumors: Do we know all the prognostic factors?
We present an analysis of 188 patients diagnosed with primary thymic tumours. The prognostic value of selected clinical and morphological factors was assessed in relation to survival. Multivariate analysis showed that the most important independent risk factor was CS IV. The risk of recurrence increased significantly in thymic carcinoma, comorbidities occurrence and weight loss. Some additional clinical factors including LDH elevation, leucocytosis, anemia may have prognostic value. BackgroundThymic epithelial tumors constitute a morphologically and clinically diverse group of rare neoplasm of the anterior mediastinum.Meth...
Source: Thoracic Cancer - January 2, 2021 Category: Cancer & Oncology Authors: Magdalena Knetki ‐Wróblewska, Dariusz M. Kowalski, Marta Olszyna‐Serementa, Maciej Krzakowski, Małgorzata Szołkowska Tags: ORIGINAL ARTICLE Source Type: research

Plasma miR ‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
ConclusionsHigh miR ‐1247‐5p, miR‐301b‐3p and miR‐105‐5p expression have been demonstrated to accelerate tumorigenesis, and these three miRNAs in plasma act as novel biomarkers for the early diagnosis of NSCLC patients.Key pointsPlasma miR ‐1247‐5p, miR‐301b‐3p and miR‐105‐5p act as novel biomarkers for early NSCLC and NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 28, 2020 Category: Cancer & Oncology Authors: Xiaohan Dong, Minghui Chang, Xingguo Song, Shanshan Ding, Li Xie, Xianrang Song Tags: ORIGINAL ARTICLE Source Type: research

Advances in study of the sequence of lung tumor biopsy and thermal ablation
This article reviews the research progress of traditional asynchronous biopsy followed by ablation, the emerging methods of synchronous biopsy followed by ablation, and synchronous ablation followed by biopsy in the last decade. AbstractPercutaneous thermal ablation is an important treatment for lung cancer and is widely used in hospitals. Puncture biopsy is generally required for pathological diagnosis before or after thermal ablation. Pathological diagnosis provides both evidence of benign and malignant lesions for ablation therapy and is of important significance for the next step in disease management. Furthermore, the...
Source: Thoracic Cancer - December 28, 2020 Category: Cancer & Oncology Authors: Fanlei Kong, Chengen Wang, Yunfang Li, Xiaoguang Li Tags: MINI REVIEW Source Type: research

Association of hOGG1 ‐Cys variants with occurrence of p53 and EGFR deletion mutations in non‐small cell lung cancer
ConclusionsWe suggest that the association ofhOGG1 Ser326Cys polymorphism with lung cancer risk could be partially explained by increases inp53 andEGFR deletion mutations.Key pointsSignificant findings of the study NSCLC patients withhOGG1‐Cys variants may have a higher risk ofp53 andEGFR deletion mutations than withhOGG1 Ser/Ser genotype.What this study adds NSCLC patients withhOGG1‐Cys variants might be helpful to predict patients having higher risk ofEGFR exon 19 deletion mutations and these patients who were treated with gefitinib or erlotinib could be a higher risk to occurEGFR T790M mutation. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 28, 2020 Category: Cancer & Oncology Authors: Ming ‐Jenn Chen, Ching‐Ju Shen, Lee Wang, Po‐Ming Chen, Chih‐Yi Chen, Huei Lee Tags: ORIGINAL ARTICLE Source Type: research

To treat or not to treat: A rare case of response to pembrolizumab ‐based immunotherapy‐chemotherapy in non‐small cell lung cancer with acute liver failure due to multiple bile duct metastases
We report a case of successful treatment with chemimmunotherapy in a young woman with obstructive jaundice and acute hepatic failure due to multiple intrahepatic bile duct metastases of NSCLC. AbstractAbout 40% of non ‐small lung cancer (NSCLC) patients have metastatic disease at the time of diagnosis. However, metastatic NSCLC in the biliary duct system is extremely rare. A high proportion of patients with acute liver failure due to advanced NSCLC do not receive any treatment due to organ dysfunction or poor p erformance status. Here, we report a case of successful treatment with chemoimmunotherapy in a young woman with...
Source: Thoracic Cancer - December 27, 2020 Category: Cancer & Oncology Authors: Inna Shaforostova, Sebastian Huss, Mirjam Gerwing, Georg Evers, Annalen Bleckmann Tags: CASE REPORT Source Type: research

Epidemiology of thymic epithelial tumors: 22 ‐years experience from a single‐institution
ConclusionsThe results indicates a clear association between the WHO histological classification and Masaoka –Koga staging system with survival. We found a higher proportion of TETs with advanced disease at diagnosis. Further research are required and collaboration is important to foster knowledge focused on classification and treatment.Key pointsSignificant findings of the studyThe WHO histological classification, the Masaoka –Koga system and surgery treatment were associated with overall survival.What this study addsTo determine prognosis factors in TETs. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 23, 2020 Category: Cancer & Oncology Authors: Patricia Rioja, Rossana Ruiz, Marco Galvez ‐Nino, Sophia Lozano, Natalia Valdiviezo, Mivael Olivera, Octavio Cabero, Maria Eugenia Guillen, Alberto De La Guerra, Edgar Amorin, Carlos Barrionuevo, Luis Mas Tags: ORIGINAL ARTICLE Source Type: research

Simultaneous bilateral pulmonary resection via single ‐utility port VATS for multiple pulmonary nodules: A single‐center experience of 16 cases
ConclusionsFor selected patients, simultaneous bilateral pulmonary resection via single ‐utility port VATS is a safe and feasible minimally invasive procedure for BMPNs. Adequate postoperative analgesia via a multimodal analgesia strategy should be used to prevent postoperative pain.Key pointsSignificant findings of the studyThe incidence of major complication after minimally invasive bilateral pulmonary resection is low for patients with good pulmonary function, but there is a relatively high incidence of minor complications and pain at the surgical site. Adequate postoperative analgesia via multimodal analgesia strateg...
Source: Thoracic Cancer - December 22, 2020 Category: Cancer & Oncology Authors: Chuan Huang, Yaoguang Sun, Qingjun Wu, Chao Ma, Peng Jiao, Yongzhong Wang, Wen Huang, Wenxin Tian, Hanbo Yu, Donghang Li, Hongfeng Tong Tags: ORIGINAL ARTICLE Source Type: research

KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma
In this study, we aimed to explore and clarify the function of KIF4A in esophageal squamous cell carcinoma (ESCC).MethodsThe microarray data were extracted from the Gene Expression Omnibus (GEO) database. We then used the database for Annotation, Visualization, and Integrated Discovery (DAVID) to perform the gene ontology function (GO) and KEGG Orthology ‐Based Annotation System (KOBAS) to perform Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed genes (DEGs). The six core candidate genes were identified using protein–protein interaction (PPI) network analysis and Cytoscape softwar...
Source: Thoracic Cancer - December 21, 2020 Category: Cancer & Oncology Authors: Xiaozheng Sun, Pengxiang Chen, Xue Chen, Wenjing Yang, Xuan Chen, Wei Zhou, Di Huang, Yufeng Cheng Tags: ORIGINAL ARTICLE Source Type: research

Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report
The prognosis in patients with NSCLC initially presenting as Trousseau's syndrome is extremely poor. This is the first report in which a patient was successfully treated with DOAC and immune ‐check point inhibitor in lung adenocarcinoma initially presenting as Trousseau's syndrome. A 60 ‐year‐old woman was urgently admitted to our hospital because of vertigo and left hemiplegia. Laboratory examination showed thrombocytopenia, high levels of D‐dimer and carcinoembryonic antigen. Brain magnetic resonance imaging (MRI) revealed multiple bilateral cerebral infarctions. Chest comp uted tomography (CT) showed an irregula...
Source: Thoracic Cancer - December 21, 2020 Category: Cancer & Oncology Authors: Yuta Nakano, Naohiko Koide, Yoshinori Koyama, Kazuhito Nitta, Tomonobu Koizumi Tags: CASE REPORT Source Type: research

Exosomal miR ‐3180‐3p inhibits proliferation and metastasis of non‐small cell lung cancer by downregulating FOXP4
ConclusionsExosomal miR ‐3180‐3p suppresses NSCLC progression by downregulating FOXP4 expression.Key pointsSignificant findings of the studyWe found that exosomal miR ‐3180‐3p suppressed NSCLC progression and also identified a miR‐3180‐3p target gene. These findings provide a foundation to determine innovative therapeutic strategies.What this study addsThis study contributes to research investigating exosomal containing miRNAs. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 21, 2020 Category: Cancer & Oncology Authors: Tengfei Chen, Yali Liu, Jun Chen, Huifei Zheng, Qiuyun Chen, Jun Zhao Tags: ORIGINAL ARTICLE Source Type: research

Feasibility of next ‐generation sequencing test for patients with advanced NSCLC in clinical practice
ConclusionsThe feasibility of Oncomine Dx in clinical practice was lower than the other CDx. The feasibility of Oncomine Dx will increase by improving the biopsy procedure.Key pointsSignificant study findings The usefulness of a next ‐generation sequencing (NGS) test has been proven in clinical trials. The feasibility of NGS is lower than other diagnostics in clinical practice especially with regard to nonsurgical biopsy.What this study adds It is necessary to improve the feasibility of NGS in clinical practice. To improve NGS feasibility, turnaround time must be shortened, and larger samples must be obtained during surg...
Source: Thoracic Cancer - December 21, 2020 Category: Cancer & Oncology Authors: Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Hiroaki Sakamaoto, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Satoru Kitazono, Noriko Yanagitani, Kengo Takeuchi, Makoto Nishio Tags: ORIGINAL ARTICLE Source Type: research

Interstitial lung disease associated with capmatinib therapy in a patient with non ‐small cell lung cancer harboring a skipping mutation of MET exon 14
Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non ‐small cell lung cancer (NSCLC) positive for skipping mutations ofMET exon 14 (METex14). Here we report a case of capmatinib ‐induced ILD in a patient with NSCLC harboring a skipping mutation ofMETex14. Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non –small cell lung cancer (NSCLC) positive for skipping mutations ofMET exon 14 (METex14). Drug ‐induced interstitial lung disease (ILD) is a relatively rare, but potentially seriou...
Source: Thoracic Cancer - December 21, 2020 Category: Cancer & Oncology Authors: Hiroaki Kanemura, Masayuki Takeda, Shigeki Shimizu, Kazuhiko Nakagawa Tags: CASE REPORT Source Type: research

First ‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
AbstractBackgroundFew studies have compared the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR ‐TKI), afatinib, with that of reversible EGFR‐TKIs. Therefore, this study assessed the effectiveness of afatinib, erlotinib, and gefitinib in terms of OS (overall survival) and progression‐free survival (PFS) inEGFR mutation ‐positive advanced non‐small cell lung cancer (NSCLC) patients.MethodsPatients withEGFR mutation ‐positive advanced NSCLC who sought treatment from December 2013 to June 2018, at a tertiary referral center were retrospectively analyzed. These patients...
Source: Thoracic Cancer - December 18, 2020 Category: Cancer & Oncology Authors: Po ‐Lan Su, Chian‐Wei Chen, Yi‐Lin Wu, Chien‐Chung Lin, Wu‐Chou Su Tags: ORIGINAL ARTICLE Source Type: research

Long non ‐coding RNA CCAT1 sponges miR‐490 to enhance cell proliferation and migration of non‐small cell lung cancer
ConclusionsThe CCAT1/miR ‐490 molecular axis has been shown to be important for the treatment of NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 16, 2020 Category: Cancer & Oncology Authors: Jingluan Wang, Nina Sun, Weizhong Han, Li Tong, Tao Xu, Guo Li Tags: ORIGINAL ARTICLE Source Type: research

Askin tumor in the chest wall
Askin's tumor is a kind of aggressive tumor and extremely rare. To date, the treatment is uncodified and the prognosis for patients with this tumor remains bleak. Herein we report a case of a giant Askin's tumor in the chest wall that following diagnosis was successfully treated with surgical resection. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 16, 2020 Category: Cancer & Oncology Authors: Lei Peng, Han ‐Yu Deng, Yi Yang, Xiao‐jun Tang, Qinghua Zhou Tags: IMAGING IN THORACIC CANCER Source Type: research

Placement of self ‐expanding metallic tracheobronchial Y stent with laryngeal mask airway using conscious sedation under fluoroscopic guidance
ConclusionsLMA assisted Y stent insertion enables airway control during the procedure. In comparison to silicone Y stent insertion, the procedure is less cumbersome, shorter in duration and does not require the use of general anesthesia or rigid bronchoscopy.Key pointsSignificant findings of the studyLMA assisted Y stent insertion enables airway control during the implantation of metallic self ‐expanding Y stent. The procedure does not require the use of general anesthesia or rigid bronchoscopy.What this study addsIn this study we present the technique and outcomes of LMA assisted Y stent insertion. This method of Y sten...
Source: Thoracic Cancer - December 16, 2020 Category: Cancer & Oncology Authors: Barak Pertzov, Evgeni Gershman, Shimon Izhakian, Shai M. Amor, Dror Rosengarten, Mordechai R. Kramer Tags: ORIGINAL ARTICLE Source Type: research

Co ‐ablation versus cryoablation for the treatment of stage III–IV non‐small cell lung cancer: A prospective, noninferiority, randomized, controlled trial (RCT)
ConclusionsWe determined that CA is noninferior to AHC in terms of efficacy and safety for the treatment of stage III –IV NSCLC. A smaller lesion area in the CA group was significantly correlated with a better DCR.Key points CA was noninferior to AHC for stage III –IV NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 15, 2020 Category: Cancer & Oncology Authors: Wuwei Yang, Yonghui An, Quanwang Li, Chuanbo Liu, Baorang Zhu, Qianfu Huang, Mengfei Zhao, Fei Yang, Huasong Feng, Kaiwen Hu Tags: ORIGINAL ARTICLE Source Type: research

Small cell lung cancer with thyroid gland oligometastasis: A case report
This study reports the case of a 72‐year‐old Japanese male. A mass lesion was identified on chest computed tomography (CT). Fluorodeoxyglucose‐positron emission tomography/computed tomography (FDG‐PET/CT) revealed a solitary thyroid gland lesion with high FDG uptake as an extrapulmonary finding, suggesting thyroid cancer or a goiter. Upon confirmation of diagnosis, treatment of SCLC was prioritized, and chemoradiotherapy for limited disease SCLC was init iated without further examination of the thyroid gland. The thyroid nodule disappeared after treatment. Two years later, the disease recurred, and a thyroid nodule...
Source: Thoracic Cancer - December 15, 2020 Category: Cancer & Oncology Authors: Toshiharu Tsutsui, Haruna Yamaki, Takashi Kumagai, Chisa Omori, Hiroaki Kobayashi, Yumiko Kakizaki, Yoshihiro Miyashita Tags: CASE REPORT Source Type: research

Functional inhibition of heat shock protein 70 by VER ‐155008 suppresses pleural mesothelioma cell proliferation via an autophagy mechanism
Conclusions: On the basis of these results, functional HSP70 inhibition by VER ‐155008 suppressed cell growth in pleural mesothelioma cells, accompanied by enhanced macroautophagy. HSP70 inhibition is thus expected to become a new strategy for treating mesothelioma.Key pointsSignificant findings of the studyIn pleural mesothelioma cells, inhibition of HSP70 function by VER ‐155008 suppressed cell proliferation accompanied by induction of autophagy which was synergistically enhanced under the starvation condition, whereas gefitinib, an EGFR‐TKI, did not show the same synergistic effect in autophagy.What this study add...
Source: Thoracic Cancer - December 15, 2020 Category: Cancer & Oncology Authors: Kosuke Sakai, Maya Inoue, Shintaro Mikami, Hiroaki Nishimura, Yoshiki Kuwabara, Akitoshi Kojima, Maiko Toda, Yumiko Ogawa ‐Kobayashi, Satoshi Kikuchi, Yusuke Hirata, Yuriko Mikami‐Saito, Hiroyuki Kyoyama, Gaku Moriyama, Michio Shiibashi, Tags: ORIGINAL ARTICLE Source Type: research

Comprehensive genomic profiling of Brazilian non ‐small cell lung cancer patients (GBOT 0118/LACOG0418)
This is the first report of the prevalence of driver mutations in Brazilian NSCLC patients using comprehensive genomic profiling. AbstractBackgroundThe aim of this study was to carry out a descriptive analysis of the somatic genetic profile and co ‐occurring mutations of non‐small cell lung cancer (NSCLC) samples from patients tested with comprehensive genomic profiling (CGP).MethodsThis was a retrospective cross ‐sectional study of patients diagnosed with NSCLC from 2013 to 2018 in Brazil and whose samples were submitted to CGP (FoundationOne or FoundationACT) using either tumor or circulating tumor DNA (ctDNA) from...
Source: Thoracic Cancer - December 14, 2020 Category: Cancer & Oncology Authors: Eldsamira Mascarenhas, Ana Caroline Gelatti, Luiz Henrique Ara újo, Clarissa Baldotto, Clarissa Mathias, Mauro Zukin, Gustavo Werutsky, Patricia Pacheco, Rafaela Gomes, Gilberto Castro, Vladmir Cordeiro Lima Tags: ORIGINAL ARTICLE Source Type: research

Two polymorphic mutations in promoter region of DNA polymerase β in relatively higher percentage of thymic hyperplasia patients
ConclusionsTwo types of mutations in the promoter region of thePolb gene, ‐168C>A and ‐188_‐187insCGCCC, are associated with thymic hyperplasia and may become a new risk factor for this disease.Key pointsSignificant findings of the studyGenetic mutations in thePolb gene are reported to be associated with different kinds of cancers. However, their relationship with thymic hyperplasia is still unclear.What this study addsFor the first time, we report that two nucleotide mutations in the promoter region of thePolb gene are closely related with thymic hyperplasia after sequencing 59 patients and 60 healthy controls in...
Source: Thoracic Cancer - December 13, 2020 Category: Cancer & Oncology Authors: Qingjun Wu, Shan Zhou, Jian Liu, Hongfeng Tong, Yaoguang Sun, Wenxin Tian, Hanbo Yu, Chuan Huang, Donghang Li, Peng Jiao, Chao Ma, Jianping Cai, Dapeng Dai Tags: ORIGINAL ARTICLE Source Type: research

Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non ‐small cell lung cancer
ConclusionsThe analytical performance of the Oncomine Dx Target Test analysis forEGFR mutations may not be comparable with conventional single gene tests due to both invalid and false ‐negative results.Key pointsSignificant findings of the study The success rate of the Oncomine Dx Target Test was significantly lower than the PNA ‐LNA PCR clamp test. Among the samples successfully analyzed, four exon 19 deletions were not detected by the Oncomine Dx Target Test.What this study adds The analytical performance of the Oncomine Dx Target Test may not be comparable with conventional single gene tests. We should revise the sa...
Source: Thoracic Cancer - December 12, 2020 Category: Cancer & Oncology Authors: Tadashi Sakaguchi, Akemi Iketani, Kazuki Furuhashi, Yuki Nakamura, Yuta Suzuki, Kentaro Ito, Kentaro Fujiwara, Yoichi Nishii, Koji Katsuta, Osamu Taguchi, Osamu Hataji Tags: ORIGINAL ARTICLE Source Type: research

Distinct clinicopathological features of pulmonary primary angiomatoid fibrous histiocytoma: A report of four new cases and review of the literature
ConclusionsPPAFH is a very unusual pulmonary primary mesenchymal tumor and the clinicopathological features are like other unusual sites counterparts, but with a smaller tumor size, related with large airway, with a tendency to exhibit benign biological behavior, withEWSR1 gene rearrangement and higher frequency ofEWSR1 ‐CREB1 gene fusion.Key pointsSignificant findings in the study: In comparison with “classic somatic” and nonpulmonary visceral angiomatoid fibrous histiocytoma, pulmonary primary angiomatoid fibrous histiocytoma display distinct clinicopathological features and prognosis.What this study adds T...
Source: Thoracic Cancer - December 12, 2020 Category: Cancer & Oncology Authors: Zheng Wang, Liping Zhang, Li Ren, Dongge Liu, Jun Du, Min Zhang, Ge Lou, Ying Song, Yin Wang, Chunyan Wu, Guiping Han Tags: ORIGINAL ARTICLE Source Type: research

New treatment of bronchopleural fistula following surgical resection of the dorsal segment of the left lower lobe: A case report
This article details a case of thoracoscopic segmentectomy of the left lower lung dorsal s egment resulting in residual subsegmental pleural fistula, and because the use of pleural adhesives made the patient's fistula inappropriate for surgical repair, we finally used bronchoscopic injury of the airway mucosa combined with an absorbable gelatin sponge and an autologous blood closure metho d for successful treatment. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 10, 2020 Category: Cancer & Oncology Authors: Ziyi Liu, Jingyu Mao, Meiqing Su, Chuangyong Mu, Tao Chen, Jun Zhao, Junhong Jiang Tags: CASE REPORT Source Type: research

Role of chemotherapy for survival in patients with second primary non ‐small cell lung cancer
ConclusionsThe therapeutic effect of chemotherapy for second primary NSCLC was found to be significant. Age, tumor size and histology were significant prognostic factors among patients who had received chemotherapy for second primary NSCLC.Key pointsSignificant findings of the study A significant therapeutic effect of chemotherapy for second primary non ‐small cell lung cancer was proven through univariate Cox regression and propensity score matching analysis. Prognostic factors for second primary non‐small cell lung cancer patients who had received chemotherapy.What this study adds Chemotherapy could be applied in cli...
Source: Thoracic Cancer - December 9, 2020 Category: Cancer & Oncology Authors: Zhile Wang, Yijun Wu, Li Wang, Liang Gong, Chang Han, Fucun Xie, Shanqing Li Tags: ORIGINAL ARTICLE Source Type: research

Heterogeneous tumor ‐immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti‐PD‐L1 antibody therapy
This study may provide new insights into the mechanism of primary resistance to chemoimmunotherapy in pulmonary carcinoid tumors. A pulmonary carcinoid tumor is a rare tumor that lacks a validated therapeutic approach for unresectable disease. Understanding the intersite tumor ‐immune heterogeneity is essential to harness the immune system for cancer therapy. However, little is known about the tumor‐immune microenvironment (TIME). Here, we describe a patient who had heterogeneous TIME between primary and metastatic carcinoid tumors which differentially responded to ch emoimmunotherapy. A 72‐year‐old man was diagnos...
Source: Thoracic Cancer - December 9, 2020 Category: Cancer & Oncology Authors: Shinya Sakata, Kosuke Imamura, Yuka Tajima, Yuiko Masuda, Ryo Sato, Chieko Yoshida, Shinichiro Okamoto, Sho Saeki, Yusuke Tomita, Takuro Sakagami Tags: CASE REPORT Source Type: research

Genomic characteristics of driver genes in Chinese patients with non ‐small cell lung cancer
This study demonstrated that the frequency of different driver genes was diverse in different age ‐gender groups, and may assist clinicians in clinical decision‐making, and assist government, pharmaceutical researchers and insurance companies in the development of public healthcare strategies in the future. AbstractBackgroundThe aim of this study was to determine the demographic profile of driver gene alterations, especially low ‐frequency gene alterations in Chinese patients with non‐small cell lung cancer (NSCLC).MethodsA total of 7395 Chinese patients with NSCLC were enrolled in the study. Next ‐generation seq...
Source: Thoracic Cancer - December 9, 2020 Category: Cancer & Oncology Authors: Xiaoyan Si, Ruili Pan, Shaohua Ma, Lin Li, Li Liang, Ping Zhang, Yuping Chu, Hanping Wang, Mengzhao Wang, Xiaotong Zhang, Li Zhang Tags: ORIGINAL ARTICLE Source Type: research

Pulmonary metastasis with coexisting pulmonary mucosa ‐associated lymphoid tissue (MALT) lymphoma 20 years after endometrioid adenocarcinoma surgery: A case report
We report a case of pulmonary metastasis with coexisting pulmonary mucosa‐associated lymphoid tissue (MALT) lymphoma 20 years after surgery for primary EA. Late pulmonary recurrence of EA (even after>20  years) should be considered during treatment planning for even early‐stage EA, and surgeons should consider aggressive resection based on this possibility. AbstractLate pulmonary metastasis from endometrioid adenocarcinoma (EA) is rare, and occurrence after>20  years is extremely rare. Here, we report a case of pulmonary metastasis with coexisting pulmonary mucosa‐associated lymphoid tissue...
Source: Thoracic Cancer - December 9, 2020 Category: Cancer & Oncology Authors: Daisuke Nakamura, Nobutaka Kobayashi, Masahisa Miyazawa, Kentaro Miura, Hidetoshi Satomi Tags: CASE REPORT Source Type: research

Short ‐term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm
This study analyzes the short ‐term oncological results and local control of solid NSCLC smaller than 2 cm, surgically treated by intentional VATS segmentectomy or lobectomy. Despite the short follow‐up, our preliminary data shows that local control is comparable for VATS lobectomy and VATS segmentectomy for patients with NS CLC
Source: Thoracic Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Marc Darras, Amaya Ojanguren, C éline Forster, Matthieu Zellweger, Jean Yannis Perentes, Thorsten Krueger, Michel Gonzalez Tags: ORIGINAL ARTICLE Source Type: research

Phase II open ‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
ConclusionsAfatinib showed similar ORR and PFS in patients with lung cancer harboring EGFRm in their ctDNA regardless of tumor EGFRm results.Key pointsSignificant findings of the studyAfatinib showed favorable ORR and PFS regardless of the tumorEGFR mutation status results, similar to the findings of previous trials assessing afatinib as first ‐line treatment ofEGFR‐mutated non‐small cell lung cancer based on tumor genotyping.What this study addsOur findings emphasize that the survival benefit of afatinib treatment can be achieved not only by appropriate dose reduction with frequent and detailed monitoring of toxicit...
Source: Thoracic Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Cheol ‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim Tags: ORIGINAL ARTICLE Source Type: research

Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound ‐guided transbronchial needle aspiration samples for next‐generation sequencing analysis
This study aimed to compare the adequacy between TBLC and EBUS‐TBNA samples for NGS an alysis.MethodsThis retrospective cohort study included patients whose lung samples were collected via TBLC or EBUS ‐TBNA and analyzed using NGS. Out of 46 genes, the number of genes in TBNA and TBLC samples that could not be assessed via NGS analysis was mainly evaluated.ResultsA total of 37 patients were included and classified into two groups (TBLC group,n = 18 and TBNA group,n = 19). The mean number of genes that could not be evaluated via NGS analysis was significantly lower in the TBLC group than in the TBNA group (0.9 vs. 10.3,...
Source: Thoracic Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Mari Tone, Minoru Inomata, Nobuyasu Awano, Naoyuki Kuse, Kohei Takada, Jonsu Minami, Yutaka Muto, Kazushi Fujimoto, Toshio Kumasaka, Takehiro Izumo Tags: ORIGINAL ARTICLE Source Type: research

Corrigendum
Thoracic Cancer, Volume 11, Issue 12, Page 3645-3645, December 2020. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 1, 2020 Category: Cancer & Oncology Tags: CORRIGENDUM Source Type: research

Issue Information
Thoracic Cancer, Volume 11, Issue 12, Page 3417-3418, December 2020. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 1, 2020 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

Simultaneous tongue metastasis from malignant pleural mesothelioma: Case report and literature review
Tongue metastasis from malignant pleural mesothelioma is rare and only a few cases have previously been documented. Here, we report a patient with MPM who presented with simultaneous tongue metastasis and review the relevant literature. AbstractMalignant pleural mesothelioma (MPM) is a rare neoplasm of the serosal membranes. MPM usually manifests as local invasion, rarely with distant haematogenous metastases in different organs. Few cases of tongue metastasis have been documented. Here, we report the case of a 68 ‐year‐old man diagnosed with malignant pleural epithelioid mesothelioma together with a simultaneous tongu...
Source: Thoracic Cancer - December 1, 2020 Category: Cancer & Oncology Authors: Chuan Huang, Xue Yang Tags: CASE REPORT Source Type: research

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non ‐small cell lung cancer in comparison with chemoradiotherapy alone
ConclusionsThe one ‐year LC rate was significantly higher in the durvalumab cohort compared with the CCRT alone cohort. Although the follow‐up period was too short to draw definitive conclusions, the study revealed that durvalumab might have a significant effect on LC.Key pointsSignificant findings of the studyEffect of durvalumab on local control after chemoradiotherapy for locally advanced non ‐small cell lung cancer is unclearWhat this study addsThe one ‐year local control rate of chemoradiotherapy followed by durvalumab was significantly higher compared with chemoradiotherapy alone. (Source: Thoracic Cancer)
Source: Thoracic Cancer - December 1, 2020 Category: Cancer & Oncology Authors: Takanori Abe, Satoshi Saito, Misaki Iino, Tomomi Aoshika, Yasuhiro Ryuno, Tomohiro Ohta, Mitsunobu Igari, Ryuta Hirai, Yu Kumazaki, Yu Miura, Kyoichi Kaira, Hiroshi Kagamu, Shin ‐ei Noda, Shingo Kato Tags: ORIGINAL ARTICLE Source Type: research

Validating impact of pretreatment tumor growth rate on outcome of early ‐stage lung cancer treated with stereotactic body radiation therapy
In this study, the same median SGR was validated in an independent dataset at a different cancer institution. Patients with high SGR tumors consistently had significantly lower survival and higher regional failure. BackgroundTo assess correlation of pretreatment specific growth rate (SGR) value of 0.43  × 10‐2 with overall and failure ‐free survival of patients with early‐stage non‐small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT).MethodsA retrospective chart review of 160 patients with pathologically confirmed stage I NSCLC treated with SBRT between June 201...
Source: Thoracic Cancer - November 30, 2020 Category: Cancer & Oncology Authors: Soha Atallah, Lisa W. Le, Andrea Bezjak, Robert MacRae, Andrew J. Hope, Jason Pantarotto Tags: ORIGINAL ARTICLE Source Type: research

Postoperative radiotherapy for pathological stage IIIA ‐N2 non‐small cell lung cancer with positive surgical margins
Postoperative radiotherapy (PORT) has been recommended to treat patients with positive surgical margins. However, the existing evidence is controversial and high ‐level evidence is lacking. In our study, the PORT group had markedly, but not statistically significant, longer median OS compared with the non‐PORT group in R1 resection patients. OS was significantly longer in the R1 resection patients receiving adjuvant CRT than the surgery alone group. BackgroundThe aim of this study was to evaluate the efficacy of postoperative radiotherapy (PORT) in stage pIIIA ‐N2 non‐small cell lung cancer (NSCLC) patients with po...
Source: Thoracic Cancer - November 27, 2020 Category: Cancer & Oncology Authors: Meng Yuan, Yu Men, Jingjing Kang, Xin Sun, Maoyuan Zhao, Yongxing Bao, Xu Yang, Shuang Sun, Zeliang Ma, Jianyang Wang, Lei Deng, Wenqing Wang, Yirui Zhai, Wenyang Liu, Tao Zhang, Xin Wang, Nan Bi, Jima Lv, Jun Liang, Qinfu Feng, Dongfu Tags: ORIGINAL ARTICLE Source Type: research

Fibrous bands associated with higher Masaoka stage and poor recurrence ‐free survival in patients with thymoma
ConclusionsThe presence of FBs in patients with thymoma was associated with higher Masaoka stage, higher recurrence rate, and poorer RFS.Key pointsSignificant findings of the studyFibrous bands (FBs) are bands of fibrosis dividing tumors into different ‐sized irregular islands. The presence of FBs is associated with higher Masaoka stage and poor recurrence‐free survival in patients with thymoma.What this study addsThe presence of fibrous bands might be associated with the malignant behavior of thymoma. Confirming the presence or absence of FBs may result in personalized medication for patients with thymoma. (Source: Thoracic Cancer)
Source: Thoracic Cancer - November 25, 2020 Category: Cancer & Oncology Authors: Kazuhiro Minami, Naoe Jimbo, Yugo Tanaka, Takahiro Uchida, Takeshi Okamoto, Nahoko Shimizu, Takefumi Doi, Daisuke Hokka, Tomoo Itoh, Yoshimasa Maniwa Tags: ORIGINAL ARTICLE Source Type: research

Clinical implication of minimal presence of solid or micropapillary subtype in early ‐stage lung adenocarcinoma
We demonstrated that only minimal presence of solid or micropapillary component was profoundly associated with aggressive clinicopathological features and poor prognosis after complete resection even in stage IA lung adenocarcinoma.Our results suggest that minimal presence of these subtypes is a strong prognostic factor which should be taken into account in the risk assessment for adjuvant chemotherapy in lung adenocarcinoma. AbstractBackgroundWe investigated the clinical features and surgical outcomes of lung adenocarcinoma with minimal solid or micropapillary (S/MP) components, with a focus on stage IA.MethodsWe enrolled...
Source: Thoracic Cancer - November 24, 2020 Category: Cancer & Oncology Authors: Sun Ha Choi, Ji Yun Jeong, Shin Yup Lee, Kyung Min Shin, Shin Young Jeong, Tae ‐In Park, Young Woo Do, Eung Bae Lee, Yangki Seok, Won Kee Lee, Ji Eun Park, Sunji Park, Yong Hoon Lee, Hyewon Seo, Seung Soo Yoo, Jaehee Lee, Seung‐Ick Cha Tags: ORIGINAL ARTICLE Source Type: research

Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini ‐review
Malignant pleural mesothelioma (MPM) is a type of cancer originating from the pleura with high aggressiveness and poor prognosis, Laboratory biomarkers have significant advantages of reduced invasiveness, low cost, and are observer ‐independent, and therefore represent a promising diagnostic tool for MPM. Here, we reviewed the diagnostic value of microRNA for MPM. Malignant pleural mesothelioma (MPM) is a type of cancer originating from the pleura with high aggressiveness and poor prognosis. A timely diagnosis is crucial to improve its prognosis. Laboratory biomarkers have significant advantages of reduced invasiveness, ...
Source: Thoracic Cancer - November 22, 2020 Category: Cancer & Oncology Authors: Yan ‐Qiu Han, Shang‐Cheng Xu, Wen‐Qi Zheng, Zhi‐De Hu Tags: MINI REVIEW Source Type: research